ClassID:

20425

A61K31/515 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring heteroatoms, e.g. piperazine; Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital

Recent Application in this class:
#1
20260108522
2026-04-23

COMPOSITIONS, FORMULATIONS, AND METHODS FOR HAIR TREATMENT

#2
20260041939
2026-02-12

METHODS FOR THE TREATMENT OF HYPERTENSION VIA TRANSCRANIAL-FOCUSED-ULTRASOUND

#3
20260041641
2026-02-12

NOVEL FORMULATION

#4
20260009759
2026-01-08

ANALYTE SENSOR

#5
20250382240
2025-12-18

3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME

#6
20250345349
2025-11-13

CANNABINOIDS IN THE TREATMENT OF EPILEPSY

#7
20250327768
2025-10-23

ENZYME IMMOBILIZED ADHESIVE LAYER FOR ANALYTE SENSORS

#8
20250319088
2025-10-16

DAPRODUSTAT FOR REDUCING FATIGUE IN A SUBJECT WITH ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE

#9
20250262229
2025-08-21

APPLICATION OF PHD2 INHIBITOR IN PREPARATION OF DRUGS FOR PREVENTION AND TREATMENT OF PLATELET THROMBUS

#10
20250249002
2025-08-07

PHARMACEUTICAL COMPOSITION FOR TOPICAL WOUND TREATMENT

#11
20250241925
2025-07-31

METHODS OF P21 SUPPRESSION FOR BONE REGENERATION AND HEALING

#12
20250171821
2025-05-29

HIF-1 ACTIVATORS AND USES THEREOF

#13
20250114359
2025-04-10

METHODS FOR INHIBITING PARASITIC GLUCOKINASE AND/OR HEXOKINASE

#14
20250051314
2025-02-13

SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING

#15
20250025449
2025-01-23

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

#16
20240415817
2024-12-19

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

#17
20240368090
2024-11-07

SOLID STATE FORMS OF DAPRODUSTAT AND PROCESS FOR THEIR PREPARATION

#18
20240316049
2024-09-26

STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION

#19
20240299538
2024-09-12

AGENT FOR USE IN THE TREATMENT OF GLIOMA

#20
20240261235
2024-08-08

Pharmaceutical Composition And Method For Treating Seizure Disorders

#21
20240228443
2024-07-11

NOVEL MANUFACTURING METHOD OF DAPRODUSTAT AND PRECURSORS THEREOF

#22
20240165048
2024-05-23

USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY

#23
20240138720
2024-05-02

ANALYTE SENSOR

#24
20240082161
2024-03-14

STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION

#25
20240066011
2024-02-29

Methods and compositions for treatment of epileptic disorders

#26
20230416209
2023-12-28

COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH

#27
20230364057
2023-11-16

BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF

#28
20230301936
2023-09-28

Use of cannabinoids in the treatment of epilepsy

#29
20230293502
2023-09-21

Methods and compositions for treatment of epileptic disorders

#30
20230293501
2023-09-21

Methods and compositions for treatment of epileptic disorders

#31
20230293489
2023-09-21

USE OF [(1R)-1-(2-CHLOROPHENYL)-2-(TETRAZOL-2-YL)ETHYL] CARBAMATE IN COMBINATION THERAPY

#32
20230293445
2023-09-21

IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMS

#33
20230285424
2023-09-14

USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES

#34
20230251276
2023-08-10

BIOMARKERS AND METHODS FOR DETECTION OF SEIZURES AND EPILEPSY

#35
20230248692
2023-08-10

COMPOUND AND METHOD FOR TREATING DISEASES AND DISORDERS

#36
20230241044
2023-08-03

TREATMENT FOR PSORIASIS AND SKIN INFLAMMATORY DISEASES

#37
20230227414
2023-07-20

Prolyl Hydroxylase Inhibitors

#38
20230225977
2023-07-20

FORMULATION COMPRISING DAPRODUSTAT

#39
20230157959
2023-05-25

Lyophilized compositions of phenobarbital sodium salt

#40
20230139158
2023-05-04

DIFFUSION RESISTANCE LAYER FOR ANALYTE SENSORS

#41
20230138407
2023-05-04

DIFFUSION RESISTANCE LAYER FOR ANALYTE SENSORS

#42
20230122670
2023-04-20

COMPOSITIONS, FORMULATIONS, AND METHODS FOR HAIR TREATMENT

#43
20230061319
2023-03-02

METHODS OF TREATING TUMORS

#44
20230042959
2023-02-09

Combination therapy

#45
20230031957
2023-02-02

Stabilization of phenobarbital sodium for injection

#46
20220395470
2022-12-15

USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY

#47
20220378717
2022-12-01

Use of cannabinoids in the treatment of epilepsy

#48
20220362224
2022-11-17

Methods and compositions for treatment of epileptic disorders

#49
20220362219
2022-11-17

RETINA REGENERATION THROUGH EPIGENETICS MANIPULATION

#50
20220354794
2022-11-10

Lyophilized Compositions of Phenobarbital Sodium Salt

#51
20220323424
2022-10-13

Methods and compositions for treatment of epileptic disorders

#52
20220313624
2022-10-06

SULFUR (VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF

#53
20220265700
2022-08-25

METHODS TO PREVENT, INHIBIT OR TREAT INTERVERTEBRAL DISC DEGENERATION

#54
20220226325
2022-07-21

Pharmaceutical composition for topical wound treatment

#55
20220214300
2022-07-07

MEMBRANE LAYERS FOR ANALYTE SENSORS

#56
20220202936
2022-06-30

Agent for use in the treatment of glioma

#57
20220202738
2022-06-30

CANNABINOIDS IN THE TREATMENT OF EPILEPSY

#58
20220193028
2022-06-23

THERAPEUTIC COMBINATIONS, LIQUID PHARMACEUTICAL COMPOSITIONS, KITS FOR THEIR PREPARATION, AND METHODS OF THEIR USE

#59
20220110879
2022-04-14

Immediate release abuse-deterrent granulated dosage forms

#60
20220105076
2022-04-07

Inhibitor for V-Atpase Activity, Antibacterial Agent, Medicine, Antibacterial Method and Screening Method

#61
20220098128
2022-03-31

3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same

#62
20220096480
2022-03-31

INDOLE MOLECULES AND USE THEREOF IN THE INHIBITION OF DNA POLYMERASES

#63
20220071990
2022-03-10

Immediate release abuse-deterrent granulated dosage forms

#64
20220031701
2022-02-03

COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH UNCONTROLLED INFLAMMATORY RESPONSES

#65
20220000799
2022-01-06

SULFUR (VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF

#66
20210401771
2021-12-30

Use of cannabinoids in the treatment of epilepsy

#67
20210356420
2021-11-18

ENZYME IMMOBILIZED ADHESIVE LAYER FOR ANALYTE SENSORS

#68
20210353751
2021-11-18

COMBINATION THERAPIES FOR TREATMENT OF INFLAMMATORY DISEASES

#69
20210347740
2021-11-11

Prolyl hydroxylase inhibitors

#70
20210267976
2021-09-02

Pharmaceutical composition for topical wound treatment

#71
20210260074
2021-08-26

SEIZURE CONTROL COMPOSITIONS AND METHODS OF USING SAME

#72
20210251993
2021-08-19

Compositions and methods for treating diseases associated with uncontrolled inflammatory responses

#73
20210251918
2021-08-19

Pharmaceutical composition and method for treating seizure disorders

#74
20210236821
2021-08-05

Systems and methods for monitoring neural activity

#75
20210228518
2021-07-29

COMPOSITIONS AND METHODS FOR TREATING REFRACTORY SEIZURES

#76
20210213000
2021-07-15

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

#77
20210186970
2021-06-24

SELECTIVE CALCIUM CHANNEL ANTAGONISTS

#78
20210121493
2021-04-29

METHODS FOR TREATING LIVER DISEASES

#79
20210113586
2021-04-22

NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES

#80
20210100755
2021-04-08

Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy

#81
20210093581
2021-04-01

Use of cannabinoids in the treatment of epilepsy

#82
20210085827
2021-03-25

Therapy for post-traumatic osteoarthritis

#83
20210085617
2021-03-25

Immediate release abuse-deterrent granulated dosage forms

#84
20210085608
2021-03-25

Lyophilized compositions of phenobarbital sodium salt

#85
20210069135
2021-03-11

THERAPEUTIC APPROACHES FOR TREATING EPILEPSY AND RELATED DISORDERS THROUGH REDUCTION OF EPILEPTOGENESIS

#86
20210008033
2021-01-14

Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy

#87
20210000805
2021-01-07

Methods and compositions for treatment of epileptic disorders

#88
20200397719
2020-12-24

Sulfur (VI) fluoride compounds and methods for the preparation thereof

#89
20200397702
2020-12-24

Pharmaceutical compositions

#90
20200384086
2020-12-10

GABA A receptor agonists for treatment of disorders influenced by dysfunction BETA cells

#91
20200383935
2020-12-10

COMPOSITION FOR TREATING SEIZURE DISORDERS

#92
20200368179
2020-11-26

USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY

#93
20200338090
2020-10-29

SEIZURE CONTROL COMPOSITIONS AND METHODS OF USING SAME

#94
20200316070
2020-10-08

Compositions and methods for inhibiting PTPN22

#95
20200300871
2020-09-24

Biomarkers and methods for detection of seizures and epilepsy

#96
20200268683
2020-08-27

Arylfluorosulfate compounds and methods

#97
20200230128
2020-07-23

PHARMACEUTICAL COMPOSITIONS

#98
20200206218
2020-07-02

PHARMACEUTICAL COMPOSITIONS

#99
20200188333
2020-06-18

ABUSE-PROOFED DOSAGE FORM

#100
20200179350
2020-06-11

Methods and compositions for treatment of epileptic disorders

#101
20200179303
2020-06-11

USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY

#102
20200157055
2020-05-21

Prolyl Hydroxylase Inhibitors

#103
20200155544
2020-05-21

Immediate release abuse-deterrent granulated dosage forms

#104
20200129572
2020-04-30

Method for treating damage induced by sleep deprivation

#105
20200129502
2020-04-30

PHARMACEUTICAL COMPOSITIONS

#106
20200078491
2020-03-12

PREVENTATIVE THERAPY FOR POST-TRAUMATIC OSTEOARTHRITIS

#107
20190365709
2019-12-05

Use Of [(1R)-1-(2-Chlorophenyl)-2-(Tetrazol-2-YL)Ethyl] Carbamate In Combination Therapy

#108
20190330124
2019-10-31

3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same

#109
20190307733
2019-10-10

Methods and compositions for treatment of epileptic disorders

#110
20190275153
2019-09-12

Compositions and methods for reducing overdose

#111
20190231698
2019-08-01

Non-extractable oral solid dosage forms

#112
20190216785
2019-07-18

Methods and compositions for treatment of epileptic disorders

#113
20190201430
2019-07-04

TREATING OCULAR NEOVASCULARIZATION

#114
20190175575
2019-06-13

METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES

#115
20190167685
2019-06-06

SELECTIVE CALCIUM CHANNEL ANTAGONISTS

#116
20190167604
2019-06-06

ARYLFLUOROSULFATE COMPOUNDS AND METHODS

#117
20190133961
2019-05-09

Immediate release abuse-deterrent granulated dosage forms

#118
20190091209
2019-03-28

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

#119
20190076430
2019-03-14

Outpatient modified rapid detoxification for addiction to alcohol and drugs

#120
20190029976
2019-01-31

ABUSE-PROOFED DOSAGE FORM

#121
20190029972
2019-01-31

Sulfur(VI) fluoride compounds and methods for the preparation thereof

#122
20190022100
2019-01-24

ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF

#123
20180344728
2018-12-06

PHARMACEUTICAL COMPOSITIONS

#124
20180344708
2018-12-06

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

#125
20180338931
2018-11-29

Use of cannabinoids in the treatment of epilepsy

#126
20180325892
2018-11-15

PHARMACEUTICAL COMPOSITIONS

#127
20180305323
2018-10-25

Prolyl hydroxylase inhibitors

#128
20180280404
2018-10-04

Inhibitors of glucose kinases, along with methods of their formation and use

#129
20180243237
2018-08-30

ABUSE-PROOFED DOSAGE FORM

#130
20180221479
2018-08-09

Agents for use in the treatment of glioma

#131
20180185367
2018-07-05

N-substituted hydroxamic acids with carbon-based leaving groups as efficient HNO donors and uses thereof

#132
20180185354
2018-07-05

Immediate release abuse-deterrent granulated dosage forms

#133
20180169298
2018-06-21

Preventative therapy for post-traumatic osteoarthritis

#134
20180161285
2018-06-14

Composition and method for treating seizure disorders

#135
20180153891
2018-06-07

Tyrosine kinase inhibition as a treatment for epilepsy

#136
20180042903
2018-02-15

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

#137
20180038848
2018-02-08

Method for determining sensitivity to fluorouracil in a subject having colorectal cancer

#138
20180036316
2018-02-08

Treatment of epileptic disorders in feline animals

#139
20180036247
2018-02-08

Pharmaceutical compositions

#140
20180021339
2018-01-25

Method for treating liver diseases of various origins

#141
20170360772
2017-12-21

PHARMACEUTICAL COMPOSITIONS

#142
20170360739
2017-12-21

Compositions and methods comprising medium chain triglycerides for treatment of epilepsy

#143
20170348305
2017-12-07

PHARMACEUTICAL COMPOSITIONS

#144
20170348304
2017-12-07

PHARMACEUTICAL COMPOSITIONS

#145
20170348303
2017-12-07

Pharmaceutical compositions

#146
20170281579
2017-10-05

Methods for rescuing phenobarbital-resistance of seizures by ANA-12 or ANA-12 in combination with CLP290

#147
20170281541
2017-10-05

LIPOSOME-BASED MUCUS-PENETRATING PARTICLES FOR MUCOSAL DELIVERY

#148
20170258912
2017-09-14

Compositions and methods for reducing overdose

#149
20170246121
2017-08-31

Use of cannabinoids in the treatment of epilepsy

#150
20170196985
2017-07-13

Sulfur(VI) fluoride compounds and methods for the preparation thereof

#151
20170188922
2017-07-06

BIOINTERFACE LAYER FOR ANALYTE SENSORS

#152
20170188921
2017-07-06

Enzyme immobilized adhesive layer for analyte sensors

#153
20170188916
2017-07-06

Membrane layers for analyte sensors

#154
20170188905
2017-07-06

BIOINTERFACE LAYER FOR ANALYTE SENSORS

#155
20170158579
2017-06-08

3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same

#156
20170157255
2017-06-08

Compositions and methods for reducing overdose

#157
20170143719
2017-05-25

Stable formulation of phenobarbital sodium injection

#158
20170143637
2017-05-25

Immediate release abuse-deterrent granulated dosage forms

#159
20170112819
2017-04-27

Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation

#160
20170079925
2017-03-23

Compositions and methods for reducing overdose

#161
20170079924
2017-03-23

Compositions and methods for reducing overdose

#162
20170042926
2017-02-16

Treating ocular neovascularization

#163
20170035758
2017-02-09

Medicinal drug with activity against gram positive bacteria, mycobacteria and fungi

#164
20170020826
2017-01-26

Stabilization of alcohol intoxication-induced cardiovascular instability

#165
20170014412
2017-01-19

Outpatient modified rapid detoxification for addiction to alcohol and drugs

#166
20170000739
2017-01-05

Abuse-proofed dosage form

#167
20160375015
2016-12-29

Pharmaceutical compositions

#168
20160367487
2016-12-22

Process for the production of an abuse-proofed dosage form

#169
20160339026
2016-11-24

TOPICAL COMPOSITIONS COMPRISING MODULATORS OF TRPM8

#170
20160317457
2016-11-03

Immediate release abuse-deterrent granulated dosage forms

#171
20160310491
2016-10-27

Selective calcium channel antagonists

#172
20160297772
2016-10-13

Prolyl hydroxylase inhibitors

#173
20160263095
2016-09-15

Methods for treating newly diagnosed multiple myeloma with 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents

#174
20160250214
2016-09-01

Method for treating liver diseases of various origins

#175
20160250203
2016-09-01

IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMS

#176
20160235752
2016-08-18

COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT

#177
20160222100
2016-08-04

Method of treating glioma

#178
20160193238
2016-07-07

HNF4-alpha ANTAGONIST AND USE THEREOF

#179
20160158183
2016-06-09

Compositions and methods comprising medium chain triglycerides for treatment of epilepsy

#180
20160129006
2016-05-12

Antiviral compounds and methods of use thereof

#181
20160106755
2016-04-21

Pharmaceutical compositions

#182
20160067240
2016-03-10

Allosteric inhibitors of thymidylate synthase

#183
20160060229
2016-03-03

N-hydroxylamino-barbituric acid derivatives

#184
20160051474
2016-02-25

Pharmaceutical compositions

#185
20160022590
2016-01-28

Compositions and methods for reducing overdose

#186
20160000786
2016-01-07

Medicinal drug with activity against gram positive bacteria, mycobacteria and fungi

#187
20150359756
2015-12-17

Use of cannabinoids in the treatment of epilepsy

#188
20150328216
2015-11-19

Indole compounds for use in treating inflammation and cancer

#189
20150320698
2015-11-12

Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy

#190
20150320685
2015-11-12

Pharmaceutical compositions

#191
20150306040
2015-10-29

Pharmaceutical compositions

#192
20150297525
2015-10-22

Pharmaceutical compositions

#193
20150265624
2015-09-24

Treatment of epileptic disorders in feline animals

#194
20150265591
2015-09-24

Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias

#195
20150218109
2015-08-06

C-Rel inhibitors and uses thereof

#196
20150141357
2015-05-21

Shikimate pathway inhibitors and the use thereof

#197
20150118303
2015-04-30

Immediate release abuse-deterrent granulated dosage forms

#198
20150118302
2015-04-30

Immediate release abuse-deterrent granulated dosage forms

#199
20150118301
2015-04-30

Immediate Release Abuse-Deterrent Granulated Dosage Forms

#200
20150118300
2015-04-30

Immediate Release Abuse-Deterrent Granulated Dosage Forms

#201
20150118295
2015-04-30

Immediate Release Abuse-Deterrent Granulated Dosage Forms

#202
20150094335
2015-04-02

Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent

#203
20150072983
2015-03-12

Use of dihydroimidazolones for the treatment of dogs

#204
20140377293
2014-12-25

Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone

#205
20140315821
2014-10-23

Treatments involving eslicarbazepine acetate or eslicarbazepine

#206
20140308344
2014-10-16

Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation

#207
20140296270
2014-10-02

STAT3 Inhibitors

#208
20140206724
2014-07-24

Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent

#209
20140206723
2014-07-24

Methods for treating amyloidosis with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione

#210
20140186404
2014-07-03

Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with antibodies

#211
20140112920
2014-04-24

Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias

#212
20140107068
2014-04-17

Marker for determination of sensitivity to anticancer agent

#213
20140088090
2014-03-27

6,7-dihydro-[1,3,4]thiadiazolo-[3,2-a][1,3]diazepin derivatives and pharmaceutical compositions containing the same as hypnotic or anesthetic agent and method for their preparation

#214
20140030322
2014-01-30

Pharmaceutical compositions

#215
20130252983
2013-09-26

ACTIVATING PHOSPHORYLATION SITE ON GLUTAMINASE C

#216
20130156795
2013-06-20

METHODS FOR INHIBITION OF CELL PROLIFERATION, SYNERGISTIC TRANSCRIPTION MODULES AND USES THEREOF

#217
20130122110
2013-05-16

Anti-human urothelial carcinoma of supercritical carbon dioxide extract of , and the preparation process and uses

#218
20130079336
2013-03-28

Treatment of prolonged status epilepticus

#219
20130071353
2013-03-21

Antiviral compounds and methods of use thereof

#220
20130065898
2013-03-14

Use of dihydroimidazolones for the treatment of dogs

#221
20120325209
2012-12-27

Method for treating early severe diffuse acute respiratory distress syndrome

#222
20120251637
2012-10-04

Abuse-proofed dosage form

#223
20120244214
2012-09-27

Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor

#224
20120237595
2012-09-20

Methods for treating amyloidosis using 4-(amino)-2-(2,6-Dioxo(3-piperidyl))- isoindoline-1,3-dione

#225
20120232066
2012-09-13

COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS

#226
20120208773
2012-08-16

PHARMACEUTICAL COMPOSITIONS WITH TETRABENAZINE

#227
20120201888
2012-08-09

Pharmaceutical compositions

#228
20120196883
2012-08-02

Selective calcium channel antagonists

#229
20120178749
2012-07-12

NS1 PROTEIN INHIBITORS

#230
20120165292
2012-06-28

METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE

#231
20120157483
2012-06-21

Method for treating liver diseases of various origins

#232
20120142694
2012-06-07

Substituted 4-hydroxypyrimidine-5-carboxamides

#233
20120135042
2012-05-31

Methods using immunomodulatory compounds for treatment of certain leukemias

#234
20120107250
2012-05-03

Abuse-proofed dosage form

#235
20120035145
2012-02-09

METHODS OF TREATING MULTIPLE MYELOMA USING MELPHALAN, PREDNISONE AND LENALIDOMIDE

#236
20120004251
2012-01-05

Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy

#237
20110319400
2011-12-29

PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN

#238
20110312984
2011-12-22

STAT3 INHIBITORS

#239
20110274740
2011-11-10

Methods of reducing symptoms in subjects using single dosage forms with tapering release rates

#240
20110224179
2011-09-15

Medicament and method of diagnosis for treating subclinical Cushing's syndrome

#241
20110183991
2011-07-28

5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME

#242
20110178045
2011-07-21

Method to induce fatty liver in animal

#243
20110135611
2011-06-09

METHODS FOR TREATING APOLIPOPROTEIN E4-ASSOCIATED DISORDERS

#244
20110008468
2011-01-13

Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders

#245
20100317738
2010-12-16

COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH NEURONAL DYSFUNCTION

#246
20100311772
2010-12-09

Method and compounds for inhibition of cell death

#247
20100311771
2010-12-09

Method of treating movement disorders using barbituric acid derivatives

#248
20100261672
2010-10-14

Pharmaceutical compositions of pyrimidine-2,4,6-triones

#249
20100260719
2010-10-14

Methods for treatment of hepatocellular carcinoma using 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione

#250
20100249165
2010-09-30

PDZ DOMAIN MODULATORS

#251
20100203001
2010-08-12

PROCESS FOR FORMING DISULFIDE BRIDGES

#252
20100197709
2010-08-05

Non-sedating barbiturate compounds as neuroprotective agents

#253
20100196369
2010-08-05

Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione

#254
20100144805
2010-06-10

Regulation of protein synthesis

#255
20100144769
2010-06-10

Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

#256
20100113444
2010-05-06

Prolyl hydroxylase inhibitors

#257
20100099711
2010-04-22

Methods and Compositions Using Immunomodulatory Compounds for The Treatment and Management of Cancers and Other Diseases

#258
20100093683
2010-04-15

Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a proteasome inhibitor

#259
20100081678
2010-04-01

Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents

#260
20100080847
2010-04-01

MEDICINAL COMPOSITIONS QUICKLY DISINTEGRATING IN THE ORAL CAVITY AND PROCESS FOR PRODUCING THE SAME

#261
20100063094
2010-03-11

METHODS FOR TREATMENT OF COLORECTAL CANCER USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE

#262
20100055116
2010-03-04

Methods and Compositions for Targeting c-Rel

#263
20100041685
2010-02-18

Stat3 inhibitors

#264
20090312352
2009-12-17

COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION

#265
20090291123
2009-11-26

Opioid Combination Wafer

#266
20090280171
2009-11-12

METHOD OF TREATMENT WITH PREDICTABLY BREAKABLE PHARMACEUTICAL TABLETS

#267
20090253724
2009-10-08

Therapeutic or prophylactic agent for leukemia

#268
20090175939
2009-07-09

Pharmaceutical compositions

#269
20090170840
2009-07-02

Inhibitors of the influenza virus non-structural 1 protein

#270
20090155265
2009-06-18

Method for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with antibodies

#271
20090123416
2009-05-14

METHODS FOR THE TREATMENT OF BLADDER CANCER USING 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE

#272
20090110724
2009-04-30

COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN

#273
20090010877
2009-01-08

Methods for treatment prostate cancer using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione

#274
20090005408
2009-01-01

PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM

#275
20080317709
2008-12-25

Methods for treating head or neck cancer using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione

#276
20080317708
2008-12-25

Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione

#277
20080292583
2008-11-27

Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroindol-2-yl)-piperidine-2,6-dione follow by autologous stem cell transplantation

#278
20080286232
2008-11-20

Methods for treating sarcoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6 dioxo(3-piperidyl))-isoindoline-1,3-dione

#279
20080247959
2008-10-09

FORM OF ADMINISTRATION SECURED AGAINST MISUSE

#280
20080219949
2008-09-11

Methods for treating brain cancer using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6 dioxo(3-piperidyl))-isoindoline-1,3-dione

#281
20080219948
2008-09-11

Methods for treatment of behcet's disease using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione

#282
20080206193
2008-08-28

Method for treatment and management of thyroid cancer using immunomodulatory compounds

#283
20080187605
2008-08-07

PREVENTING PATHOLOGICAL NERVE CELL SUICIDE (NEUROAPOPTOSIS) IN IMMATURE NERVOUS SYSTEMS

#284
20080145368
2008-06-19

Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias

#285
20080132529
2008-06-05

Method of improving bioavailability for non-sedating barbiturates

#286
20080113993
2008-05-15

BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS

#287
20080075772
2008-03-27

PHARMACEUTICAL COMPOSITIONS HAVING NOVEL SCORING PATTERNS AND METHODS OF USING THOSE COMPOSITIONS

#288
20080070925
2008-03-20

SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION

#289
20080027057
2008-01-31

Use of dihydroimidazolones for the treatment of dogs

#290
20070299020
2007-12-27

Methods for treatment of ovarian, colorectal or pancreatic cancer using 4-(aminno)-2(2,6-dioxo(3-piperidyl)-isoindoline-1,3-dione

#291
20070292498
2007-12-20

Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers

#292
20070259903
2007-11-08

ANTI-VIRAL USES FOR ANALOGS OF BARBITURIC ACID

#293
20070238672
2007-10-11

CO-ADMINISTRATION OF ADENOSINE A1 RECEPTOR ANTAGONISTS AND ANTICONVULSANTS

#294
20070225253
2007-09-27

Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases

#295
20070191404
2007-08-16

Pharmaceutical compositions of pyrimidine-2,4,6-triones

#296
20070183980
2007-08-09

DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE

#297
20070072886
2007-03-29

Method of treating movement disorders using barbituric acid derivatives

#298
20070043034
2007-02-22

Chlorine Ion Uptake Modulators and Uses Thereof

#299
20070039064
2007-02-15

Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse

#300
20070039063
2007-02-15

Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse